Daily 1-pager M&A Snapshot for Deal Makers
Oct 3 (Reuters) – Shares of LogicBio Therapeutics (LOGC.O) skyrocketed on Monday after Britain’s AstraZeneca’s (AZN.L) said it would buy the U.S.-based gene therapy developer at a rare 660% premium for $68 million.
Source
Author: unknown
21 Invest Mulls Sale of $500M Eye-Care Firm Sifi - IntroductionIn a move that could reshape the eye-care industry, Italian private equity firm 21 Invest is reportedly considering the sale of Sifi,...
AbbVie's Transformative Acquisition of Cerevel Therapeutics AbbVie's $8.7 billion acquisition of Cerevel Therapeutics is set to reshape the neuroscience landscape, unlocking innovative therapies and...
Rite Aid's Elixir Buyer Must Pay Additional $50M in Ch. 11 Sale In a pivotal move for its bankruptcy restructuring, embattled pharmacy chain Rite Aid has secured an additional $50 million from...
Pieris Pharma Stock Surges on Palvella Therapeutics Merger Deal Pieris Pharmaceuticals (PIRS) saw its stock soar by over 70% on July 24, 2024, following the announcement of an all-stock merger deal...